Consequently, whereas inhibition of MCL-1, and also slightly BCL-xL, by dinaciclib is sufficient to kill SCLC cells, NSCLC cells are more resistant due to a general lower apoptotic priming and plasticity to rapidly adapt through anti-apoptotic proteins to support survival. The gene discussed is BCL2L1; the disease is small cell lung carcinoma.